- CRB-601 shows dose-dependent antitumor activity correlating with increased binding to αvβ8 in pre-clinical tumor models
- CRB-601 enhances anti-PD-1 immunotherapy efficacy and induces long-lasting tumor-specific cytotoxic T-cells
- IND submission for CRB-601 on track for 2H 2023
NORWOOD, MA, USA I April 17, 2023 I Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced details of new pre-clinical data on CRB-601, its avβ8 blocking antibody, presented as a poster at the 2023 American Association for Cancer Research (AACR) annual meeting, held April 14-19, 2023 in Orlando, FL.
The poster titled “CRB-601, an avβ8 blocking antibody, prevents activation of TGFβ and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment” explores the relationship between CRB-601 antitumor activity, PK and its binding to the αvβ8 receptor in the tumor. In addition, the impact on TGFβ pathway signaling and tumor immune cell population are also presented. Tumor growth was evaluated in mice bearing orthotopically implanted murine breast cancer EMT6 or colon cancer MC38 and treated with CRB-601.
CRB-601 exhibited dose dependent tumor growth inhibition (TGI) in the EMT6 tumor model which was significantly augmented in combination with anti-PD1 therapy. These effects were associated with changes in tumor micro-environment (TME) immune cell populations with marked increases in infiltrating T cells, NK cells and M1 polarized macrophages. Efficacy correlated with cell surface αvβ8 occupancy by CRB-601. CRB-601 treatment downregulated phosphorylation of SMAD proteins pSMAD2 and pSMAD3, consistent with blockade of the canonical TGFβ signaling pathway.
Rachael Brake, PhD, Chief Scientific Officer of Corbus stated: “We are building on our early efficacy. We can now demonstrate that CRB-601 has robust anti-tumor activity alone and as a combination partner with anti-PD-1 and that these effects are associated with documented receptor engagement, a reduction of TGFb1 levels in the tumor micro-environment (TME), and inhibition of downstream canonical TGFb signaling. Together this data reinforces the potential of this new approach in blocking activation of TGFb locally in the TME.”
About Corbus
Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ current pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
SOURCE: Corbus Pharmaceuticals
Post Views: 241
- CRB-601 shows dose-dependent antitumor activity correlating with increased binding to αvβ8 in pre-clinical tumor models
- CRB-601 enhances anti-PD-1 immunotherapy efficacy and induces long-lasting tumor-specific cytotoxic T-cells
- IND submission for CRB-601 on track for 2H 2023
NORWOOD, MA, USA I April 17, 2023 I Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced details of new pre-clinical data on CRB-601, its avβ8 blocking antibody, presented as a poster at the 2023 American Association for Cancer Research (AACR) annual meeting, held April 14-19, 2023 in Orlando, FL.
The poster titled “CRB-601, an avβ8 blocking antibody, prevents activation of TGFβ and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment” explores the relationship between CRB-601 antitumor activity, PK and its binding to the αvβ8 receptor in the tumor. In addition, the impact on TGFβ pathway signaling and tumor immune cell population are also presented. Tumor growth was evaluated in mice bearing orthotopically implanted murine breast cancer EMT6 or colon cancer MC38 and treated with CRB-601.
CRB-601 exhibited dose dependent tumor growth inhibition (TGI) in the EMT6 tumor model which was significantly augmented in combination with anti-PD1 therapy. These effects were associated with changes in tumor micro-environment (TME) immune cell populations with marked increases in infiltrating T cells, NK cells and M1 polarized macrophages. Efficacy correlated with cell surface αvβ8 occupancy by CRB-601. CRB-601 treatment downregulated phosphorylation of SMAD proteins pSMAD2 and pSMAD3, consistent with blockade of the canonical TGFβ signaling pathway.
Rachael Brake, PhD, Chief Scientific Officer of Corbus stated: “We are building on our early efficacy. We can now demonstrate that CRB-601 has robust anti-tumor activity alone and as a combination partner with anti-PD-1 and that these effects are associated with documented receptor engagement, a reduction of TGFb1 levels in the tumor micro-environment (TME), and inhibition of downstream canonical TGFb signaling. Together this data reinforces the potential of this new approach in blocking activation of TGFb locally in the TME.”
About Corbus
Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ current pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
SOURCE: Corbus Pharmaceuticals
Post Views: 241
